Get all your news in one place.

100's of premium titles.
One app.

Get all your news in one place.

100's of premium titles. One news app.

The Latest Breaking News from Global Blood rapeutics

Benzinga's Top Ratings Upgrades, Downgrades For August 9, 2022

Benzinga's Top Ratings Upgrades, Downgrades For August 8, 2022

Benzinga's Top Ratings Upgrades, Downgrades For August 8, 2022

12 Health Care Stocks Moving In Thursday's Intraday Session

12 Health Care Stocks Moving In Thursday's Intraday Session

From analysis to the latest developments in health,
read the most diverse news in one place.

inkl

Recap Of Tuesday's Biotech Catalysts - End of The Day Summary

European Commission (EC) has approved AbbVie’s (NYSE:ABBV) lead asset RINVOQ (upadacitinib 45 mg [induction dose] and 15 mg and 30 mg [maintenance doses]) for the treatment of adult patients with moderately to severely active ulcerative colitis. AbbVie shares traded in a range of $150.33 to $153.56 on a day volume…

Looking Into Global Blood Therapeutics's Return On Capital Employed

According to Benzinga Pro data, during Q1, Global Blood Therapeutics (NASDAQ:GBT) posted sales of $55.16 million. Earnings were up 7.03%, but Global Blood Therapeutics still reported an overall loss of $81.42 million.

Sickle cell: Just half of nurses and doctors feel confident about treating illness, report finds

Exclusive: The experiences of more than 1,300 people people living with the illness, carers and healthcare professionals, were examined

The Independent UK

Global Blood Therapeutics Earnings Perspective: Return On Capital Employed

According to data from Benzinga Pro, during Q1, Global Blood Therapeutics's (NASDAQ:GBT) reported sales totaled $55.16 million. Despite a 7.03% increase in earnings, the company posted a loss of $81.42 million.

inkl

Read news from The Economist, FT, and more,
with one subscription

Recap: Global Blood Therapeutics Q1 Earnings

Recap: Global Blood Therapeutics Q1 Earnings

Global Blood Therapeutics (NASDAQ:GBT) reported its Q1 earnings results on Wednesday, May 4, 2022 at 04:05 PM. Here's what investors need to know about the announcement.

Looking Into Global Blood Therapeutics's Return On Capital Employed

Looking Into Global Blood Therapeutics's Return On Capital Employed

Global Blood Therapeutics (NASDAQ:GBT) brought in sales totaling $56.10 million during Q4 according to data provided by Benzinga Pro. However, earnings decreased 23.37%, resulting in a loss of $87.58 million.

1

Organisations

European Commission

Western Digital

Palantir Technologies

Bed, Bath & Beyond

From analysis to the latest developments in health,
read the most diverse news in one place.

inkl

Topics

Sickle Cell Disease

Ulcerative Colitis

Macular Degeneration

Amyotrophic lateral sclerosis

inkl

Read news from The Economist, FT, and more,
with one subscription

Places

357,750 stories

135,420 stories

Fourteen days free

Download the app

One app. One membership.
100+ trusted global sources.

Download on the AppStore

Get it on Google Play